In recent years, there has been an increasing call for the medical community to address a significantly overlooked health issue – Female Genital Schistosomiasis (FGS). A chronic gynaecological disease prevalently affecting girls and women in sub-Saharan Africa, FGS is caused by the parasitic worm Schistosoma (S.) haematobium. Despite its extensive impact, FGS remains largely in the shadows of global health priorities. A compelling study recently published in the British Medical Bulletin urges both researchers and healthcare professionals to take action against this debilitating disease (DOI: 10.1093/bmb/ldad034).

The Severity of FGS

Female Genital Schistosomiasis is more than an affliction of the body; its consequences are profoundly detrimental to the societal, psychological, and reproductive facets of women’s lives. As the British Medical Bulletin elucidates, FGS is not merely a parasitic infection. It is associated with sexual dysfunction, reproductive tract morbidity, and notably, an increased prevalence of HIV and cervical precancer lesions. The plight of those suffering from FGS in sub-Saharan Africa is exacerbated by the lack of resources and attention given to this disease.

Diagnostic and Treatment Challenges

Diagnosing FGS poses significant challenges due to the requirement of costly equipment and specialized training, which are rare commodities in resource-poor settings. Adding to the complexity, there is an absence of standardized methods for both individual and population-based screening, leading to underestimation of the disease burden and subsequent misguided resource allocation.

For those diagnosed, treatment recommendations gleaned from public health guidelines lack rigorous backing from clinical evidence on efficacy. To accurately gauge the disease burden and to determine targeted interventions, effective diagnostic methods and clinical trials dedicated to optimizing FGS treatment are urgently needed.

The Need for Integration within SRH Programmes

The study stresses the necessity for FGS surveillance to be integrated within wider schistosomiasis control strategies and other sexual and reproductive health (SRH) programmes. The interplay between FGS and other SRH infections remains poorly understood, underscoring the importance of longitudinal studies to broaden epidemiological insights on comorbidities and integration into SRH interventions.

Innovative Screening Approaches

There is a glimmer of hope on the horizon through the emerging interest in decentralizing strategies for FGS screening and diagnosis. Home-based self-sampling with handheld colposcopes operated by primary healthcare workers could be a game-changer for at-risk women with limited healthcare access. These innovative approaches promise a new direction for FGS surveillance, could potentially improve disease management, and facilitate the integration of FGS control into primary healthcare services.

Future Paths and Clinical Trials

The path forward includes the prediction of the cost-effectiveness of such diagnostic strategies. Understanding their affordability and feasibility is vital for their implementation within the overburdened health systems of sub-Saharan Africa. Additionally, clinical trials to establish definitive, evidence-based treatments for FGS are imperative for improved patient outcomes.


FGS’s continued neglect in global health discussions not only perpetuates the suffering of millions of women but also allows for the perpetuation of a substantial yet preventable public health issue. Researchers and healthcare providers need to recognize FGS as a priority and engage in concerted efforts to bring forth solutions. The call to action by this recently published study (DOI: 10.1093/bmb/ldad034) cannot be overstated; it’s time to bring FGS out of neglect and into the realm of controlled and treatable diseases.


1. Lamberti, O., Bozzani, F., Kita, K., & Bustinduy, A. L. (2024). Time to bring female genital schistosomiasis out of neglect. British Medical Bulletin. DOI: 10.1093/bmb/ldad034.
2. World Health Organization. (2020). Female genital schistosomiasis: a neglected disease of women.
3. Engels, D., Hotez, P. J., Ducker, C. (2022). The Global Burden of Female Genital Schistosomiasis. The Lancet Infectious Diseases.
4. Kjetland, E. F., Ndhlovu, P. D., Gomo, E., Mduluza, T., Midzi, N., Gwanzura, L., … & Gundersen, S. G. (2014). Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS.
5. Friedman, J. F., Mital, P., Kanzaria, H. K., Olds, G. R., & Kurtis, J. D. (2007). Schistosomiasis and pregnancy. Trends in Parasitology.


1. Female Genital Schistosomiasis
2. FGS treatment and diagnosis
3. Schistosomiasis in sub-Saharan Africa
4. Schistosomiasis and HIV risk
5. Schistosomiasis control programs

© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For Permissions, please email: